Timeline

Yu Wei

Group Leader

09 Dec 2024

publication

Enhanced hepatitis B virus-specific immunity by combined neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B infection.

09 Dec 2024

publication

Enhanced hepatitis B virus-specific immunity by combined neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B infection

16 May 2024

publication

CALCOCO2/NDP52 associates with RAB9 to initiate an antiviral response to hepatitis B virus infection through a lysosomal degradation pathway.

19 Dec 2023

publication

NDP52 mediates an antiviral response to hepatitis B virus infection through Rab9-dependent lysosomal degradation pathway.

21 Dec 2022

publication

Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters

28 Sep 2016

publication

Single-nucleotide-resolution mapping of HBV promoters in infected human livers and hepatocellular carcinoma

05 Nov 2015

publication

Deficiency of multidrug resistance 2 contributes to cell transformation through oxidative stress

06 Jul 2015

project

Molecular mechanisms regulating hepatitis B virus replication and liver carcinogenesis

01 Aug 2013

publication

LIM-only protein FHL2 activates NF-κB signaling in the control of liver regeneration and hepatocarcinogenesis.

28 Feb 2013

publication

The LIM-only protein FHL2 controls mesenchymal cell osteogenic differentiation and bone formation through Wnt5a and Wnt10b

15 Jan 2013

publication

The four and a half LIM-only protein 2 (FHL2) activates transforming growth factor β (TGF-β) signaling by regulating ubiquitination of the E3 ligase Arkadia

11 Jul 2012

publication

The four and a half LIM-only protein 2 regulates liver homeostasis and contributes to carcinogenesis

18 May 2010

publication

Molecular biology of the hepatitis B virus and role of the X gene

28 Apr 2010

publication

Deficiency of the LIM-only protein FHL2 reduces intestinal tumorigenesis in Apc mutant mice

01 Dec 2008

publication

Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer

19 Nov 2008

publication

The LIM-only protein FHL2 mediates ras-induced transformation through cyclin D1 and p53 pathways

31 Mar 2008

publication

The LIM-only protein FHL2 regulates cyclin D1 expression and cell proliferation

01 Feb 2007

publication

Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer

01 May 2006

publication

The LIM-only protein FHL2 is a negative regulator of E4F1

13 Feb 2003

publication

Identification of the LIM protein FHL2 as a coactivator of beta-catenin

01 Sep 2002

publication

Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features

01 Jun 2002

publication

Genetic alterations and oncogenic pathways in hepatocellular carcinoma

27 Jan 2000

publication

Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas

01 Sep 1999

publication

A little guide for advanced search:

Timeline

Enhanced hepatitis B virus-specific immunity by combined neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B infection.

Enhanced hepatitis B virus-specific immunity by combined neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B infection

CALCOCO2/NDP52 associates with RAB9 to initiate an antiviral response to hepatitis B virus infection through a lysosomal degradation pathway.

NDP52 mediates an antiviral response to hepatitis B virus infection through Rab9-dependent lysosomal degradation pathway.

Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters

Single-nucleotide-resolution mapping of HBV promoters in infected human livers and hepatocellular carcinoma

Deficiency of multidrug resistance 2 contributes to cell transformation through oxidative stress

Molecular mechanisms regulating hepatitis B virus replication and liver carcinogenesis

LIM-only protein FHL2 activates NF-κB signaling in the control of liver regeneration and hepatocarcinogenesis.

The LIM-only protein FHL2 controls mesenchymal cell osteogenic differentiation and bone formation through Wnt5a and Wnt10b

The four and a half LIM-only protein 2 (FHL2) activates transforming growth factor β (TGF-β) signaling by regulating ubiquitination of the E3 ligase Arkadia

The four and a half LIM-only protein 2 regulates liver homeostasis and contributes to carcinogenesis

Molecular biology of the hepatitis B virus and role of the X gene

Deficiency of the LIM-only protein FHL2 reduces intestinal tumorigenesis in Apc mutant mice

Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer

The LIM-only protein FHL2 mediates ras-induced transformation through cyclin D1 and p53 pathways

The LIM-only protein FHL2 regulates cyclin D1 expression and cell proliferation

Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer

The LIM-only protein FHL2 is a negative regulator of E4F1

Identification of the LIM protein FHL2 as a coactivator of beta-catenin

Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features

Genetic alterations and oncogenic pathways in hepatocellular carcinoma

Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas

Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation